Department of Food Chemistry and Nutrition, Jagiellonian University Medical College, Kraków, Poland.
Medical Center DIAGNOZA, Kraków, Poland.
Int J Clin Pract. 2021 Sep;75(9):e14484. doi: 10.1111/ijcp.14484. Epub 2021 Jun 30.
Autoimmune thyroid diseases, including Hashimoto's thyroiditis, are the most common ones among autoimmune diseases. The reported effects of selenium supplementation on the course of Hashimoto's thyroiditis are not consistent. It is therefore important to continue this line of research.
The participants received selenium in the form of sodium selenite(IV) at a dose of 100 µg/day for 6 months.
Newly diagnosed and previously untreated Hashimoto's thyroiditis with euthyroidism or subclinical hypothyroidism. A total of 36 patients (aged 20 to 52 years) qualified for this study, of whom 29 women were successfully enrolled and completed the intervention.
Both before and after supplementation the following parameters in serum were tested: anti-thyroid peroxidase antibodies, thyroid function indicators, selenium as well as antioxidant status parameters and other biochemical parameters (lipid profile, glucose). Iodine supply and subjective assessment of physical and psychological health were also monitored.
Selenium supplementation decreased significantly level of anti-thyroid peroxidase antibodies what might have had a stabilizing effect on thyroid function, as values of thyroid parameters were within normal range before and at the end of the study. Mean level of selenium among patients was not different to healthy people in Poland. Median of ioduria was within normal range.
The study shows a potential way of protective effect of selenium in limiting development of overt hypothyroidism. The increase in the concentrations of Se and SELENOP in the serum of patients verifies successful supplementation and good compliance, but did not affect the antioxidant status parameters measured.
自身免疫性甲状腺疾病（包括桥本甲状腺炎）是最常见的自身免疫性疾病之一。目前关于补硒对桥本甲状腺炎病程影响的报道结果并不一致，因此有必要继续开展这方面的研究。
研究对象连续 6 个月每天接受 100μg 硒酸钠（IV）形式的硒补充治疗。
新诊断且未经治疗的桥本甲状腺炎伴甲状腺功能正常或亚临床甲状腺功能减退症。共有 36 例（年龄 20 至 52 岁）符合本研究条件，其中 29 名女性成功入组并完成干预。
在补充前后检测血清中的以下参数：甲状腺过氧化物酶抗体、甲状腺功能指标、硒及抗氧化状态参数和其他生化参数（血脂谱、血糖）。还监测了碘供应情况以及身体和心理健康的主观评估。
硒补充显著降低了甲状腺过氧化物酶抗体的水平，这可能对甲状腺功能具有稳定作用，因为研究前后甲状腺参数值均在正常范围内。患者的硒平均水平与波兰健康人群无差异。尿碘中位数在正常范围内。
该研究表明硒具有限制显性甲状腺功能减退症发展的潜在保护作用。患者血清中 Se 和 SELENOP 浓度的增加证实了补充的成功和良好的依从性，但并未影响所测量的抗氧化状态参数。
